Esophageal Squamous Cell Carcinoma

Showing 1 - 25 of 216

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 30, 2023

NLR and Its Association With Efficacy of Immunochemotherapy in

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Nov 10, 2023

    Esophageal Squamous Cell Carcinoma Trial in Shanghai (Tirelizumab, Nab paclitaxel, Carboplatin)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Shanghai, Shanghai, China
      Ruijin hospital, Shanghai jiaotong university school of medicine
    Nov 6, 2023

    Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Head and Neck Squamous Cell Carcinoma
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 25, 2023

    Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

    Recruiting
    • Esophageal Squamous Cell Carcinoma
      • Shijiazhuang, Hebei, China
        Department of Thoracic Surgery, Fourth Hospital of Hebei Medical
      Oct 25, 2023

      Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers Trial (ABBV-400)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • +6 more
      • (no location specified)
      Oct 10, 2023

      Esophageal Squamous Cell Carcinoma Trial in China (1% Lugol's iodine solution, 5% Lugol's iodine solution)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • 1% Lugol's iodine solution
      • 5% Lugol's iodine solution
      • Ankang, Shaanxi, China
      • +5 more
      Sep 25, 2023

      Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • +2 more
      • Shanghai, Shanghai, China
        Shanghai chest hospital
      Sep 24, 2023

      Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)

      Enrolling by invitation
      • Esophageal Squamous Cell Carcinoma
      • Nanjing, China
        The First Affiliated Hospital of Nanjing Medical University
      Sep 19, 2023

      Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

      Not yet recruiting
      • Diffuse Astrocytoma, IDH-Mutant
      • +20 more
      • NEO212 Oral Capsule
      • +8 more
      • (no location specified)
      Sep 18, 2023

      Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma Trial in United States (MT-8421, Nivolumab)

      Recruiting
      • Non Small Cell Lung Cancer
      • +10 more
      • Los Angeles, California
      • +4 more
      Sep 5, 2023

      Esophageal Squamous Cell Carcinoma Trial (LY01015, Fluorouracil, Cisplatin)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • (no location specified)
      Aug 28, 2023

      Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Split-course hypo-CCRT
      • +2 more
      • Guangzhou, Guangdong, China
        Sun yat-sen University Cancer Center
      Aug 26, 2023

      Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage Trial (LBL-007,

      Not yet recruiting
      • Esophageal Cancer
      • +2 more
      • (no location specified)
      Aug 21, 2023

      Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
      • (no location specified)
      Aug 17, 2023

      Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)

      Recruiting
      • Neoadjuvent
      • +3 more
      • Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
      • Xi'an, Shaanxi, China
      • +2 more
      Aug 17, 2023

      Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Cadonilimab combined Anlotinib
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Aug 6, 2023

      Esophageal Squamous Cell Carcinoma Trial in Shantou (Tislelizumab)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Shantou, Guangdong, China
        Cancer Hospital of Shantou University Medical College
      Aug 2, 2023

      Esophageal Squamous Cell Carcinoma Trial in Wuhan (no intervention)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • no intervention
      • Wuhan, Hubei, China
        Renmin hosptial of Wuhan University
      Jul 29, 2023

      Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • +2 more
      • LDRT+CFRT
      • +2 more
      • Shanghai, China
      • +1 more
      Aug 3, 2023

      Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Beijing (Esophagectomy)

      Active, not recruiting
      • Esophageal Squamous Cell Carcinoma
      • Oligometastatic Disease
      • Esophagectomy
      • Beijing, China
      • +1 more
      Jul 11, 2023

      Esophageal Squamous Cell Carcinoma Trial (XH-30002 capsule, Afatiinb tablet)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • XH-30002 capsule
      • Afatiinb tablet
      • (no location specified)
      Jun 25, 2023

      Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Intensity-modulated radiotherapy (IMRT)
      • +3 more
      • Wuhan, Hubei, China
        Renmin hosptial of Wuhan University
      Jun 16, 2023

      Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer Trial (VLS-1488)

      Not yet recruiting
      • Advanced Solid Tumor
      • +15 more
      • (no location specified)
      Jun 2, 2023

      Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

      Not yet recruiting
      • Minimal Residual Disease
      • Esophageal Squamous Cell Carcinoma
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Jun 10, 2023